A phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer

J. A. Roberts*, A. P. Kudelka, D. R. Spriggs, F. Muggia, J. Lurain, W. Grove, C. Kowal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The platinum analog CI-973 was selected for clinical study because it is associated with fewer and milder toxicities than either cisplatin or carboplatin in experimental animals, and because it has activity against cisplatin-resistant cell lines in vitro. In this Phase 2 study, 31 women with platinum-resistant or recurrent ovarian carcinoma were treated with CI-973. Three patients achieved a complete response, defined as the disappearance of all measurable disease. The median Kaplan-Meier survival time was estimated to be approximately 7 months from the start of treatment. The most frequently occurring drug-related toxicities were neutropenia, nausea, vomiting, asthenia, anemia, abdominal pain, and diarrhea. Most toxicities were mild or moderate and none resulted in withdrawal from treatment. Despite this favorable toxicity profile, the low response rate of 10% does not support further clinical development of CI-973 as treatment for ovarian cancer.

Original languageEnglish (US)
Pages (from-to)257-260
Number of pages4
JournalInternational Journal of Gynecological Cancer
Volume6
Issue number4
DOIs
StatePublished - 1996

Keywords

  • CI-973
  • Phase 2 study
  • ovarian cancer
  • platinum analog

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'A phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this